Hearts and Minds Investments (HM1) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
31 Mar, 2026Executive summary
Total net investment income rose 45% to $83.4 million for the year ended 30 June 2024, with profit after tax up 55% to $50.9 million year-over-year.
Total comprehensive income after tax was $53.5 million, down 15% from the prior year, reflecting lower other comprehensive income.
The investment portfolio delivered an 11.7% pre-tax return, driven by strong technology holdings and improved Conference Portfolio performance.
Fully franked dividends of 14 cents per share were paid, with an increased half-yearly dividend of 7.5 cents per share declared for October 2024.
Share price increased from $2.26 to $2.58, narrowing the discount to pre-tax NTA to 17% and resulting in a 20% total shareholder return for FY24.
Financial highlights
Net asset value increased from $675.5 million to $697.4 million, after paying $32.0 million in dividends.
Pre-tax NTA per share rose to $3.09 (from $2.90), post-tax NTA per share to $3.05 (from $2.95).
Realised investment gains were $33.3 million; unrealised gains were $53.6 million.
Basic and diluted EPS was 22.26 cents, up from 14.35 cents year-over-year.
Cash and cash equivalents at year-end were $65.9 million.
Outlook and guidance
Board aims to maintain fully franked dividends, subject to cash reserves and franking credits.
Ongoing improvement in investment performance is expected to further narrow the share price discount to NTA.
Future performance is dependent on portfolio returns and broader market conditions; no specific forward guidance provided.
Latest events from Hearts and Minds Investments
- FY25 saw a 25.5% pre-tax return, 24% shareholder return, and $9.5M donated to research.HM1
H2 202531 Mar 2026 - Flat portfolio returns and a major write-down led to a sharp drop in half-year profit.HM1
H1 202617 Feb 2026 - Strong returns, higher dividends, and active management drive performance and philanthropy.HM1
AGM 20243 Feb 2026 - Strong returns, rising dividends, and major medical research funding highlighted at AGM.HM1
AGM 202526 Nov 2025 - Record half-year profit and robust portfolio returns drive NTA and dividend growth.HM1
H1 20255 Jun 2025